Skip to main content

Table 2 Survival and prognostic factors

From: Radiotherapy plus temozolomide in elderly patients with glioblastoma: a “real-life” report

 

Median survival (months)

12 months survival (%)

Univariate analysis

Multivariate analysis

HR [95%CI]

p

HR [95%CI]

p

Age

< 75.5 years

5.6

18.6

    

 ≥ 75.5 years

5.1

17.8

1.03 [0.69–1.53]

0.88

0.76 [0.49–1.20]

0.25 # $

KPS

< 70

3.2

7.5

    

 ≥ 70

7.8

25

0.52 [0.34–0.77]

< 0.01

0.70 [0.45–1.09]

0.11 #

Gender

Female

4.5

15.7

    

Male

6.1

20.7

0.70 [0.47–1.05]

0.08

0.71 [0.47–1.08]

0.10 # $

MGMT status

Methylated

5.9

12.1

    

Unmethylated

4.8

17.5

1.14 [0.72–1.82]

0.57

  

Type of surgery

Biopsy

4.8

50

    

Resection

13.5

13

0.43 [0.24–0.77]

< 0.05

0.47 [0.26–0.86]

< 0.05 #

RPA class

I-II

13.5

50

    

III

5.5

15.4

1.95 [1.07–3.57]

< 0.05 *

2.15 [1.17–3.95]

< 0.05 $ *

IV

3.1

7.9

3.08 [1.65–5.76]

< 0.001 *

2.87 [1.53–5.41]

< 0.01 $ *

Type of treatment

HFRT + TMZ

5.5

18.9

    

Stupp

9.6

24.2

0.74 [0.46–1.20]

0.22¤

  

HFRT

3.9

8.8

    

HFRT + TMZ or Stupp

5.9

22.9

0.6 [0.40–0.92]

< 0.05§

0.54 [0.33–0.88]

< 0.05 # $ §

  1. Abbreviations: HR hazard ratio, HFRT Hypofractionated radiotherapy, TMZ Temozolomide, KPS Karnofsky Performance Status. #: Multivariate analysis model 1 adjusted for age, gender, KPS and type of surgery, $: Multivariate analysis model 2 adjusted for gender, and RPA class.* compared with RPA class I-II. ¤ compared with HFRT+TMZ; §: compared with HFRT